Failure of PI3K inhibitors as cancer treatment is attributed to several factors [137,138,139], including (but not limited to) mutations in members of the PI3K/AKT/NF-κB pathway that is due to NF-κB-induced resistance to apoptosis. This evidence concerns the gene AKT1 and cancer.